Clinical trials: Active Population
Postmenopausal Women
Tibolone Endometrium Study (Study 32972)(P06470)
Tibolone has been registered for the treatment of climacteric symptoms and for the prevention of postmenopausal osteoporosis. This is a 2-year study to further confirm the endometrial safety of tibolone in comparison with CE/MPA.
- Trial name
- THEBES (NCT00745108)
- Testing
- tibolone, Tibolone 2.5 mg, CE/MPA
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypertension
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80…
- Trial name
- NCT00926289
- Testing
- Telmisartan, Hydrochlorothiazide
- Where
- 106 sites in United States, Bulgaria and 6 more
- Volunteers
- 894 people
- Sponsor
- Boehringer Ingelheim
Prostatic Hyperplasia
Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms
Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms
- Trial name
- NCT02245490
- Testing
- Tamsulosin HCl controlled release capsules
- Volunteers
- 153 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Phase III Trial to Evaluate the Efficacy and Safety of LC15-0444 Compared With Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes
Double-blind, randomized, multicenter, multinational (South Korea and India), parallel group study The study was divided into three parts: part 1 was a screening period started with an initial 2 weeks of exercise/diet program…
- Trial name
- NCT01602003
- Testing
- LC15-0444 25mg bid, LC15-0444 50mg qd, Sitagliptin 100mg qd
- Where
- South Korea
- Volunteers
- 425 people
- Sponsor
- LG Life Sciences
Low Back Pain
RN624 In Adult Patients With Chronic Low Back Pain
The primary objective of this study is to evaluate the analgesic efficacy of RN624 compared with placebo and compared with naproxen in the treatment of adult patients with chronic low back pain.
- Trial name
- NCT00584870
- Testing
- Naproxen, PF-04383119 (RN624)
- Where
- 38 sites in United States
- Volunteers
- 220 people
- Sponsor
- Pfizer
Moderate Active Ulcerative Colitis
Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of E6007 once daily for 8 weeks in Japanese participants with moderate active ulcerative colitis.
- Trial name
- NCT03018054
- Testing
- E6007
- Where
- 64 sites in Japan
- Volunteers
- 147 people
- Sponsor
- EA Pharma Co., Ltd.
Atrial Fibrillation (AF)
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to…
- Trial name
- PACIFIC-AF (NCT04218266)
- Testing
- BAY2433334, Apixaban
- Where
- 93 sites in Austria, Belgium and 12 more
- Volunteers
- 755 people
- Sponsor
- Bayer
Rheumatoid Arthritis
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
The purpose of the study is to evaluate the improvements in signs and symptoms of rheumatoid arthritis (RA) for fostamatinib compared to placebo or adalimumab in patients who are Disease-Modifying anti-rheumatic drug (DMARD)…
- Trial name
- OSKIRA -4 (NCT01264770)
- Where
- 105 sites in United States, Bulgaria and 11 more
- Volunteers
- 644 people
- Sponsor
- AstraZeneca
HCC - Hepatocellular Carcinoma
Phase IIb Study of AST-3424 in Patients With AKR1C3-high Expressing Advanced Hepatocellular Carcinoma
The goal of this clinical trial is to learn if drug AST-3424 works to treat AKR1C3 high expressing advanced hepatocellular carcinoma after failure of systemic therapy with immune checkpoint inhibitors.
- Trial name
- NCT07310173
- Testing
- AST-3424, Regorafenib Tablets
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang Hisun Pharmaceutical Co. Ltd.
Chronic Troublesome Sialorrhea, Parkinson's Disease
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of…
- Conditions
- Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
- Trial name
- SIAXI (NCT02091739)
- Testing
- IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units)
- Where
- 31 sites in Germany, Poland
- Volunteers
- 184 people
- Sponsor
- Merz Pharmaceuticals GmbH
Correction of Nasolabial Folds
A Randomized, Multicenter, Evaluator-Blinded, Active-Controlled, Parallel-Group Investigation to Evaluate the Performance and Safety of YVOIRE® Classic Plus Versus Comparator for Temporary Correction of Nasolabial Folds
A Study to Evaluate the Performance and Safety of YVOIRE Classic plus on NLF.
- Trial name
- NCT05106751
- Testing
- Hyaluronic acid dermal filler
- Where
- Germany
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- LG Chem
Chronic Obstructive Pulmonary Disease
Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)
Primary Objective To demonstrate that CHF 1535 pMDI is non-inferior to Symbicort® Turbohaler® in terms of pulmonary function (change from baseline in pre-dose morning FEV1 at Week 24) in patients with COPD.
- Trial name
- FORSYYN (NCT03888131)
- Where
- 53 sites in China
- Volunteers
- 750 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Peripheral Neuropathy, Neuropathic Pain
Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the effectiveness of ADL5859 in relieving the pain associated with diabetic peripheral neuropathy (DPN) compared with placebo and duloxetine (a marketed drug approved for the treatment of…
- Trial name
- NCT00603265
- Testing
- ADL5859, Duloxetine
- Where
- 27 sites in United States
- Volunteers
- 226 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Psoriasis Vulgaris
This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream
This trial is a randomized, investigator-blind, multicentre, vehicle- and comparator-controlled, parallel-group trial with the purpose of evaluating the efficacy, safety and convenience of the MC2-01 cream.
- Trial name
- NCT03802344
- Testing
- MC2-01 cream, Cal/BDP combination, Vehicle
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 498 people
- Sponsor
- MC2 Therapeutics
Multiple Sclerosis
IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis
The purpose of this study is to determine the effects, both good and bad, of IPX056 on subjects and their spasticity. This study will also determine the relationship between the amount of IPX056 in blood and the effects on…
- Trial name
- NCT00488839
- Testing
- IPX056 20 mg, IPX056 40 mg, Encapsulated Baclofen 20 mg
- Where
- 31 sites in United States, Canada and 3 more
- Volunteers
- 173 people
- Sponsor
- Impax Laboratories, LLC
Hypertension
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
- Trial name
- NCT00219063
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 844 people
- Sponsor
- Novartis
Open Angle Glaucoma, Ocular Hypertension
A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension
To evaluate the efficacy of once daily dosing with SPARC's novel ophthalmic formulation of bimatoprost compared with Lumigan 0.01% in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT03927443
- Testing
- SDP-133, Lumigan
- Sponsor
- Sun Pharmaceutical Industries Limited
Diabetic Neuropathy, Painful
A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)
- Trial name
- NCT02215252
- Testing
- PF-05089771 150 mg, Pregabalin 300 mg, PF-05089771 150 mg + Pregabalin 300 mg
- Where
- 32 sites in United States
- Volunteers
- 141 people
- Sponsor
- Pfizer
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects previously treated with Erythropoiesis-Stimulating Agents (ESAs)
- Trial name
- MIYABI ND-M (NCT03350347)
- Testing
- Molidustat (BAY85-3934), Darbepoetin alfa
- Where
- 59 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Bayer
Parkinson Disease
The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa
The main objective of the study is to explore firstly, then further evaluate and confirm the efficacy between Pramipexole Sustained Release (SR) versus Pramipexole Immediate Release (IR) on nocturnal symptoms (as measured by the…
- Trial name
- NCT03521635
- Testing
- Pramipexole SR, Pramipexole IR
- Where
- 12 sites in China
- Volunteers
- 98 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.